TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03345264

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online, interactive self-help program
Description: Participants will receive access to the program, which provides: In-depth information specific to cancer sites and treatments, guidance on medical options for cancer-related sex or fertility problems, personalized goal-setting with progress tracking and relapse prevention, self-help exercises on overcoming sexual, relationship, and dating problems, videos of survivors' stories, and video vignettes with actors.
Study: NCT01592721

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: EGFR Antisense DNA
Description: EGFR AS will be administered by direct intratumoral injection using direct visualization, endoscopy, or imaging-guidance (ultrasound) as clinically determined. Patients will receive a total of up to 4 weekly intratumoral injections of EGFR antisense (or less if there is no identifiable tumor) starting 2 weeks prior to radiation. Patients will receive standard radiation 70 Gy/200 cGy/daily, 5 days/week, with concurrent cetuximab 250 mg/m2, after a loading dose of 400 mg/m2 2 weeks prior to starting radiation.
Study: NCT01197768

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nutrition Intervention
Description: Participants randomized to the intervention group receive a comprehensive nutrition assessment and a in-home intervention with follow-up calls from a Registered Dietician who will addresses their risk for becoming under-nourished at multiple levels.
Study: NCT01079819

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BMS-708163
Description: Capsule, Oral, 50 mg, once daily, 1 Day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BMS-708163
Description: Capsule, Oral, 125 mg, once daily, 14 Days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Capsule, Oral, 0 mg, One daily, 1 Day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Capsule, Oral, 0 mg, One daily, 14 Day
Study: NCT03684681

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Peer Navigator Intervention
Description: A peer navigator delivers an intervention to current drug users and uses their own training and real- life experiences to help people meet their goals.
Study: NCT03424408

Intervention type: DRUG
Group type: OTHER
Intervention: Aspirin 81 mg
Description: Healthy volunteers will receive 5 days of aspirin 81 mg daily. Following cessation of aspirin, daily blood samples will be collected for serum thromboxane B2 measurement
Study: NCT01204619

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intensive training group
Description: an extra structured patient centric training program on PD technique and diet according to the developed training curriculum
Study: NCT03684681

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Social Work Intervention
Description: A hospital social workers uses their own previous training to help people meet their goals.
Study: NCT00924352

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasatinib
Description: Dasatinib tablets will be administered continuously starting on Day 1, Cycle 1 once daily (QD).Dose Level 2;140 mg QD,Dose Level 1;100 mg QD,Dose Level 0 (Starting Dose);100 mg QD,Dose Level - 1;100 mg QD,Dose Level - 2;70 mg QD.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ixabepilone
Description: Ixabepilone, for injection 15 mg supplied with diluent for ixabepilone, 8 mL. Dose Level 2;20 mg/m2,Dose Level 1;20 mg/m2,Dose Level 0 (Starting Dose);16 mg/m2,Dose Level - 1;12 mg/m2,Dose Level - 2;12 mg/m2.
Study: NCT02125331

Intervention type: PROCEDURE
Intervention: Device: Blood pressure monitoring with GE Healthcare CARESCAPE B650 Patient Monitor-Patient Side Module (PSM) or Patient Data Module (PDM)
Description: 3-15 Non-Invasive Blood Pressure readings on the CARESCAPE B650 Patient Monitor equipped with PSM-Datex-Ohmeda and PDM-SuperSTAT NIBP measurement devices during non-emergent heart catheterization

Intervention type: PROCEDURE
Intervention: Device: Blood pressure monitoring with GE Healthcare CARESCAPE B650 Patient Monitor-Patient Side Module (PSM) or Patient Data Module (PDM)
Description: 3-15 Non-Invasive Blood Pressure readings on the CARESCAPE B650 Patient Monitor equipped with PSM-Datex-Ohmeda and PDM-SuperSTAT NIBP measurement devices during non-emergent heart catheterization
Study: NCT00137436

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel Phase 1 - escalating doses (60 and 75 mg/m2), intravenous therapy (IV), administered every 3 weeks. Phase 2 - Phase 1 optimal combination dose (75 mg/m2, IV, every 3 weeks).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Prednisone Phase1/2 - 5 mg twice a day (BID), oral.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SU011248
Description: SU011248 Phase 1 - escalating doses (12.5, 37.5, and 50 mg), oral, administered on a 2-weeks on, 1-week off daily regimen (Schedule 2/1). Phase 2 - Phase 1 optimal combination dose (37.5 mg/day, oral, Schedule 2/1).
Study: NCT00165646

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E3810
Description: E3810 5mg: once daily orally for 4 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E3810
Description: E3810 10mg: once daily orally for 4 weeks
Study: NCT03372044

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06865571 Immediate release suspension
Description: Suspension
Study: NCT00165646

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo: once daily orally for 4 weeks
Study: NCT03165591

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: V3-P
Description: one tablet of V3-P given once daily for 2 months
Study: NCT00701727

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ezetimibe
Description: 1 tablet,10mg, once a day, for 7 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 tablet, once a day, for 7 weeks
Study: NCT00710034

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oral tobacco
Description: Snus

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nicotine Gum
Description: 4 mg Nicotine gum
Study: NCT02078713

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Contraceptive Decision Support Tool
Description: The decision support tool:~* Provides an educational session about different aspects of contraception~* Elicits patient preferences about different aspects of contraception~* Identifies potential contraindications to certain contraceptive methods~* Allows the patient to view details about and compare available contraceptive methods~* Suggests methods most appropriate based on the patient's preferences~* Collects questions the patient may have for her provider~* Generates a printout the patient can bring to her contraceptive counseling visit
Study: NCT02757066

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NPC-15 Granules Lower Dose
Description: NPC-15 granule which contains 1mg melatonin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NPC-15 Granules Higher Dose
Description: Melatonin granule which contains 4 mg melatonin

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: NPC-15 Placebo Granule
Description: Melatonin placebo granule which does not contains melatonin.
Study: NCT01182623

Intervention type: OTHER
Intervention: Observation of surface patterns of polyps
Description: examination of the surface patterns of polyps using FICE and indigo carmine dye spray
Study: NCT00726817

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Butyrate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Butyrate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Butyrate
Study: NCT03539172

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib Mesylate
Description: Apatinib Mesylate will be administered orally at 500 mg once daily from 2 weeks before the beginning of radiotherapy until the end of whole radiotherapy course
Study: NCT00414310

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine
Description: 20 mg/m\^2 IV over 1 hour daily for 5 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine
Description: 20 mg/m\^2 IV over 1 hour daily for 5 days.
Study: NCT02464488

Intervention type: OTHER
Intervention: Plasma drug concentrations
Description: Measure of plasma concentrations of the anticoagulant drug taken by the patient
Study: NCT00981799

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nelarabine
Description: Dose will be assigned at study entry. Nelarabine will be given IV over 60 minutes (given at hours 0 to 1) on days 1 through 5.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nelarabine
Description: Dose will be assigned at study entry. Nelarabine will be given IV over 60 minutes (given at hours 0 to 1) on days 1 through 5.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nelarabine
Description: Dose will be assigned at study entry. Nelarabine will be given IV over 60 minutes (given at hours 0 to 1) on days 1 through 5.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nelarabine
Description: Dose will be assigned at study entry. Nelarabine will be given IV over 60 minutes (given at hours 0 to 1) on days 1 through 5.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: 100 mg/m2/day IV over 2 hours (given at hours 1 to 3) on days 1 through 5

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: 100 mg/m2/day IV over 2 hours (given at hours 1 to 3) on days 1 through 5

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: 100 mg/m2/day IV over 2 hours (given at hours 1 to 3) on days 1 through 5
Study: NCT03372044

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06865571 Slow release MR tablets
Description: Modified release tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06865571 Fast release MR tablets
Description: Modified release tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06865571 Immediate release tablets
Description: Immediate release tablets
Study: NCT02901405

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Negative Pressure Wound Therapy (ActivVAC, KCI)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard dressings
Description: Current absorbent dressing is 'tegaderm with absorbent pad' (3M)
Study: NCT04378556

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Nutritional coaching
Description: Participants were provided with nutrition education and a per-meal protein prescription followed by 9 weeks of nutritional coaching.
Study: NCT00074204

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: carboplatin
Description: Carboplatin IV over 30-60 minutes on day 1. Treatment repeats every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: Carboplatin IV over 30-60 minutes on day 1. Treatment repeats every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: docetaxel
Description: Arm I (immediate docetaxel): Patients receive immediate docetaxel IV over 1 hour on day 1.~Arm II (delayed docetaxel): Patients are observed until first evidence of disease progression and then receive docetaxel IV over 1 hour on day 1.~In both arms, treatment repeats every 3 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity.
Study: NCT03639324

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sub-Trial: Dose combination 2-2
Description: 150 mg BID of idelalisib + 100 mg QD of venetoclax
Study: NCT01570660

Intervention type: DRUG
Group type: NO_INTERVENTION
Intervention: Pioglitazone
Description: 12 weeks of pioglitazone treatment
Study: NCT01451814

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Positive Psychotherapy for smoking cessation
Description: 6 sessions of individual behavioral smoking cessation counseling that incorporates techniques from Positive Psychotherapy to increase positive affect and reduce negative affect prior to and after quitting smoking. Intervention includes 8 weeks of transdermal nicotine patch.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine polacrilex
Description: 8 weeks of nicotine patch
Study: NCT00981799

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: 100 mg/m2/day IV over 2 hours (given at hours 1 to 3) on days 1 through 5

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Dose will be assigned at study entry, IV as a 30-60 minute infusion (given at hours 3 to 4) on days 1 through 5.
Study: NCT01451814

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nicotine polacrilex
Description: 8 weeks of nicotine patch
Study: NCT00981799

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Dose will be assigned at study entry, IV as a 30-60 minute infusion (given at hours 3 to 4) on days 1 through 5.
Study: NCT01451814

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Relaxation training
Description: Instructions in progressive muscle relaxation

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral smoking cessation treatment
Description: Counseling on techniques to manage triggers and avoid smoking
Study: NCT00981799

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Dose will be assigned at study entry, IV as a 30-60 minute infusion (given at hours 3 to 4) on days 1 through 5.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Dose will be assigned at study entry, IV as a 30-60 minute infusion (given at hours 3 to 4) on days 1 through 5.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Give between day 29 and 36 or when ANC\>750 and PLTS\>75,000 - whichever comes first (but not prior to day 22) at the dose defined by age below, ideally in conjunction with BM evaluation.~Given intrathecally at the dose defined by age below. 8 mg for patients age greater than or equal to 1, but \<2 years of age 10 mg for patients age greater than or equal to 2, but \<3 years of age 12 mg for patients greater than or equal to 3, but \< 9 years of age 15 mg for patients greater than or equal to \>9 years of age
Study: NCT01451814

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Behavioral smoking cessation treatment
Description: Counseling on techniques to manage triggers and avoid smoking
Study: NCT00981799

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Give between day 29 and 36 or when ANC\>750 and PLTS\>75,000 - whichever comes first (but not prior to day 22) at the dose defined by age below, ideally in conjunction with BM evaluation.~Given intrathecally at the dose defined by age below. 8 mg for patients age greater than or equal to 1, but \<2 years of age 10 mg for patients age greater than or equal to 2, but \<3 years of age 12 mg for patients greater than or equal to 3, but \< 9 years of age 15 mg for patients greater than or equal to \>9 years of age
Study: NCT02236559

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Noninvasive positive pressure ventilation (NIPPV)
Description: Patients will be fit with an oronasal mask using a fitting gauge that will be applied by a respiratory therapist or other clinician skilled in management of NIPPV. Initial pressures will be at low end of suggested range but can be increased as rapidly as necessary to alleviate respiratory distress. Targets should be to lower respiratory rate to the low 20s and achieve tidal volumes of 6-8 ml/kg ideal body weight. If patients find pressures uncomfortably high, they can be lowered as necessary by 1 to 2 cmH2O decrements to enhance tolerance. EPAP (PEEP) can also be adjusted upward as needed to reduce triggering effort (by counterbalancing auto-PEEP) or to improve oxygenation.~FIO2 will be 1.0 initially to assure adequate oxygenation, but should be adjusted promptly to maintain an FIO2 of no greater than 0.6 with an EPAP (PEEP) of not more than 10 cm H2O to maintain a PaO2 \> 88%.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vapotherm
Description: Patients will be fit with a Vapotherm adult nasal cannula that will be applied by a respiratory therapist or other clinician skilled in management of HFT. Initial flow will be set to 35 L/min but can be decreased or increased as rapidly as necessary to alleviate respiratory distress and optimize patient comfort. Targets should be to lower respiratory rate to the low 20s and with a HFT flow rate between 20 to 35 L/min. Starting temperature will be between 35 to 37 C; if patients find the gas temperature to be uncomfortable, it can be lowered as necessary down to 33 C to enhance tolerance. FIO2 will be 1.0 initially to assure adequate oxygenation, but should be adjusted promptly to maintain an FIO2 of no greater than 0.6 to maintain a PaO2 \> 88%.
Study: NCT04106141

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 6 weeks changing of archwire
Description: changing the archwire after 6 weeks instead of 4 weeks

Intervention type: OTHER
Group type: OTHER
Intervention: 4 weeks changing of archwire
Description: changing the archwire every 4 weeks
Study: NCT04215198

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Move3™ (NEM® brand eggshell membrane + KD PUR® brand fish oil)
Description: Dietary supplement combination for the support of joint health.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT00608673

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pimecrolimus 1% cream
Description: a very thin coat of pimecrolimus 1% cream, twice daily topically to the facial lesions of discoid lupus erythematosus

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: betamethasone valerate 0.1% cream
Description: A very thin coat of betamethasone valerate 0.1% cream, twice daily to facial lesions of discoid lupus erythematosus for 8 weeks.
Study: NCT00942058

Intervention type: OTHER
Intervention: Serum and urinary CA9 level
Description: Blood and urinary samples are collected before treatment and at 1, 3, 6, 9 and 12 months.
Study: NCT03178396

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: melatonin
Description: controlled release, 9 mg taken 30 minutes before bedtime x 6 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: melatonin
Description: controlled release, 9 mg taken 30 minutes before bedtime x 6 weeks
Study: NCT00981799

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Give between day 29 and 36 or when ANC\>750 and PLTS\>75,000 - whichever comes first (but not prior to day 22) at the dose defined by age below, ideally in conjunction with BM evaluation.~Given intrathecally at the dose defined by age below. 8 mg for patients age greater than or equal to 1, but \<2 years of age 10 mg for patients age greater than or equal to 2, but \<3 years of age 12 mg for patients greater than or equal to 3, but \< 9 years of age 15 mg for patients greater than or equal to \>9 years of age

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Give between day 29 and 36 or when ANC\>750 and PLTS\>75,000 - whichever comes first (but not prior to day 22) at the dose defined by age below, ideally in conjunction with BM evaluation.~Given intrathecally at the dose defined by age below. 8 mg for patients age greater than or equal to 1, but \<2 years of age 10 mg for patients age greater than or equal to 2, but \<3 years of age 12 mg for patients greater than or equal to 3, but \< 9 years of age 15 mg for patients greater than or equal to \>9 years of age

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Filgrastim
Description: 5 micrograms/kg/day IV or SC will begin on Day 6 and end when the ANC is \> 1000/mm3 for two consecutive days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Filgrastim
Description: 5 micrograms/kg/day IV or SC will begin on Day 6 and end when the ANC is \> 1000/mm3 for two consecutive days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Filgrastim
Description: 5 micrograms/kg/day IV or SC will begin on Day 6 and end when the ANC is \> 1000/mm3 for two consecutive days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Filgrastim
Description: 5 micrograms/kg/day IV or SC will begin on Day 6 and end when the ANC is \> 1000/mm3 for two consecutive days.
Study: NCT01566279

Intervention type: DRUG
Group type: OTHER
Intervention: Everolimus
Description: All patients will receive everolimus 10mg q.d.
Study: NCT01355848

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief Intervention for Suicidality
Description: Focuses on behavioral elements of care, including building rapport, functional analysis, and crisis planning
Study: NCT01380249

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PDM08
Description: To assess the tolerability and safety of increasing multiple doses administration of PDM08: 560 μg, 1.12, 2.24, 3.5, 14, 28 and 56 mg administered twice a week for four weeks in patients with advanced solid tumours for which there is no standard therapy or they are refractory to it.
Study: NCT04632524

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MgSO4
Description: Group (M) n=30 will receive Mg So4 pre-induction as an intravenous bolus 20mg/kg over 10 minutes and maintenance dose intraoperative 5/mg/kg/h intravenous and discontinued just before the end of the surgery. Group (S) n=30 will receive saline in equal volume. The surgeon , anesthesiologist and the person who will collect the data will be blinded for the prepared solution. The solution will be prepared by an expert anesthesia nurse.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: MgSO4
Description: Group (M) n=30 will receive Mg So4 pre-induction as an intravenous bolus 20mg/kg over 10 minutes and maintenance dose intraoperative 5/mg/kg/h intravenous and discontinued just before the end of the surgery. Group (S) n=30 will receive saline in equal volume. The surgeon , anesthesiologist and the person who will collect the data will be blinded for the prepared solution. The solution will be prepared by an expert anesthesia nurse.
Study: NCT02722668

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: TBI
Description: Both Arms: 200 cGy on Day -1

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: TBI
Description: Both Arms: 200 cGy on Day -1
Study: NCT02647528

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Chromogenix Regenlite Transform Treatment
Description: Pulse Dyed Laser - 7mm spot size 3-3.6 J/cm2

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Chromogenix Regenlite Transform Placebo
Description: Pulse Dyed Laser - 7mm spot size 0 J/cm2
Study: NCT00789113

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Extended Release Lamotrigine